Oncology Research and Treatment最新文献

{"title":"37. Deutscher Krebskongress: Fortschritt gemeinsam gestalten: zusammen - gezielt - zukunftsfähig: ABSTRACTS.","authors":"","doi":"10.1159/000550849","DOIUrl":"10.1159/000550849","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"49 Suppl. 1","pages":"1-335"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146195141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating the Evolving Landscape of Advanced Genitourinary Cancer Treatment.","authors":"Marcus Hentrich, Stefanie Zschäbitz","doi":"10.1159/000548229","DOIUrl":"10.1159/000548229","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"1-3"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moving Tumor-Agnostic Therapy to the Big Stage: Translational and Molecular Oncology Highlights from the ESMO Congress 2025.","authors":"Elisabeth Tregel, Damian T Rieke, Annalen Bleckmann, Christoph Benedikt Westphalen, Ina Pretzell, Sebastian Lange, Michael Quante, Linus D Kloker","doi":"10.1159/000551042","DOIUrl":"10.1159/000551042","url":null,"abstract":"<p><p>The ESMO Congress 2025 in Berlin marked a milestone in precision oncology with the introduction of the first dedicated tumor-agnostic track, reflecting the shift from organ-based to molecularly defined cancer therapy. Across multiple sessions, updated data on biomarker-driven and pathway-based treatments demonstrated how targeted therapies can transcend histologic boundaries. Highlights included long-term results for approved tumor-agnostic agents (e.g., NTRK and BRAF-directed therapies, HER2-targeted antibody-drug conjugates [ADCs], as well as next-generation KRAS inhibitors, HER2- and TROP2-directed tyrosine kinase inhibitors and ADCs, and novel targets such as MTAP deletions, MET amplification, CD44v9 and MUC1. In parallel, advances in synthetic-lethality strategies beyond PARP inhibition and the clinical implementation of ctDNA-based minimal-residual-disease monitoring showcased how molecular profiling and liquid biopsies are reshaping treatment selection and response assessment. Taken together, these developments highlight the growing momentum in biomarker-guided and molecularly driven cancer care.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"330-340"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146227501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life and Patient-Reported Outcomes: Highlights from the European Society for Medical Oncology Annual Meeting Congress 2025.","authors":"Anna Franziska Hamm, Thomas Michaeli","doi":"10.1159/000550831","DOIUrl":"10.1159/000550831","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"298-300"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frontline Pembrolizumab or Methotrexate in Elderly, Frail, or Cisplatin-Ineligible Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of the Randomized Phase 2 Study ELDORANDO (AIO-KHT-0115).","authors":"Konrad Klinghammer, Ullrich Graeven, Philipp Ivanyi, Andreas Dietz, Dennis Hahn, Stephan Hackenberg, Stefan Kasper, Marlen Haderlein, Daniel Pink, Ingeborg Tinhofer, Marina Schaaf, Disorn Sookthai, Viktor Grünwald","doi":"10.1159/000549947","DOIUrl":"10.1159/000549947","url":null,"abstract":"<p><strong>Introduction: </strong>Elderly, frail, or cisplatin-ineligible patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) have a poor prognosis. To date, no standard of care has been defined for this population.</p><p><strong>Methods: </strong>The randomized, open-label phase 2 study was conducted to determine whether first-line treatment with pembrolizumab (PEM) is superior to methotrexate (MTX) in elderly, frail, or cisplatin-ineligible patients with R/M HNSCC not amenable to local therapies. Patients were randomized 1:1 to receive PEM 200 mg q3w or MTX 40 mg/m2 IV weekly until disease progression or unacceptable toxicity. The primary end point was overall survival after 1 year (1YOS); secondary endpoints were time to failure of strategy (TTFS) at 1 year, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).</p><p><strong>Results: </strong>Of 100 planned participants, 47 (23 in the PEM and 24 in the MTX group) were enrolled. The trial was terminated prematurely. Efficacy did not differ between the treatment arms (1YOS 17.4% for PEM vs. 37.5% for MTX [p = 0.12]). ORR was 17.4% with PEM vs. 12.5% with MTX (p = 0.70), TTFS at 1 year was 91% vs. 100% (p = 0.47), median PFS was 1.8 vs. 2.7 months (p = 0.83), and median OS was 6.1 vs. 9.7 months (p = 0.50), respectively. PD-L1 expression did not impact primary and secondary endpoints. Safety parameters favored PEM.</p><p><strong>Conclusion: </strong>ELDORANDO failed to demonstrate benefit of PEM over MTX regarding 1YOS, ORR, PFS, or OS. The optimal treatment strategy for fragile patients remains to be determined.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"237-245"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145810983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Statement.","authors":"","doi":"10.1159/000550500","DOIUrl":"10.1159/000550500","url":null,"abstract":"<p><p>The authors' accepted manuscript \"TACE Combined with Hepatic Arterial Infusion of Nivolumab for Inhibiting Tumor Angiogenesis in Hepatocellular Carcinoma\" [Oncol Res Treat. 2025; https://doi.org/10.1159/000549516] by Sujing Zhang, Zheng Zheng, Changwang Zhang, Xueqian Liu, Xinlei Shi, and Wenhua Ma has been retracted by the Publisher and the Editor on behalf of the authors.After peer review, the accepted, unedited manuscript was published online as Early View. Subsequently, the authors requested to withdraw the manuscript from the journal. As the article is not approved by the authors for publication, we are retracting the Early View accepted, unedited manuscript.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"236"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Navigation in Breast Cancer Management: Process Cost Analysis Based on German Case Studies.","authors":"Jasmin Nachtigall, Ann-Cathrine Froitzheim, Melina Sophie Kurte, Robert Dengler, Manfred Welslau, Steffi Busch, Heidi Schumacher, Florian Kron","doi":"10.1159/000548889","DOIUrl":"10.1159/000548889","url":null,"abstract":"<p><p><p>Introduction: The high incidence of breast cancer combined with the growing number of innovative and complex treatment options, such as oral tumor therapies, is increasingly shifting oncological care to the outpatient sector. This development is placing substantial capacity burdens on office-based providers. Evidence suggests that the use of \"treatment navigators\" - qualified nonphysician personnel tasked with coordination and support - can improve efficiency and reduce workload for physicians. This study aimed to assess the economic effects of task delegation in the German outpatient breast cancer from the healthcare provider´s perspective.</p><p><strong>Methods: </strong>The study followed a three-step approach: (1) identification, (2) quantification, and (3) evaluation of resources. For (1), a micro-costing-based process analysis was conducted to capture resource use in outpatient breast cancer care. Relevant services were identified via literature review. For (2), the (a) duration of individual services and (b) delegation potential were quantified through structured interviews with physicians in hematology, oncology, and gynecological oncology. In (3), personnel costs were calculated using the currently applicable wages for physician and defined in the German Uniform Evaluation Standard (EBM) and analogously for medical assistants. Based on service durations and delegation opportunities, potential cost and time savings per case study were estimated.</p><p><strong>Results: </strong>Eleven service categories comprising 40 individual tasks were identified in step 1. Four expert interviews were conducted in step 2. Full delegation (100%) was consistently reported for the performance of electrocardiograms, laboratory diagnostics, and the administration of medications. In contrast, delegation rates varied widely for tasks such as patient monitoring (0-100%), detailed medical history (0-90%), and documentation (0-87%). The highest time and cost-saving potentials were observed in the categories of patient counseling (up to 22.5 EUR or 45 min), monitoring (up to 51.75 EUR or 95.5 min), supportive measures (up to 39 EUR or 78 min), and disease management program consultations (up to 46.82 EUR or 93.6 min).</p><p><strong>Conclusion: </strong>These findings highlight significant heterogeneity in delegation practices and efficiency gains across outpatient oncology and gynecology practices, reflecting structural differences in practice organization and staff qualification. Legal and financial frameworks in Germany support structured delegation, yet practical implementation remains inconsistent. Delegation to treatment navigators offers significant potential to improve efficiency and patient-centered care, particularly in light of rising case numbers and the growing relevance of oral tumor therapies. However, further research is needed to validate these findings and support broader implementation. </p>.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"192-202"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12707876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145293072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse Effects and Functional Outcome after Salvage Lymph Node Dissection in Prostate Cancer.","authors":"Ruth Himmelsbach, Julia Franz, August Sigle, Moritz Weishaar, Larissa Lang, Simon Spohn, Constantinos Zamboglou, Anca-Ligia Grosu, Wolfgang Schultze-Seemann, Christian Gratzke, Markus Grabbert, Cordula Jilg","doi":"10.1159/000549126","DOIUrl":"10.1159/000549126","url":null,"abstract":"<p><strong>Introduction: </strong>The goal of our study was to generate a standardized assessment of postoperative complications and functional results in patients undergoing salvage lymph node dissection (sLND) in a multimodal setting with prior primary therapy and possibly multiple courses of radiation due to nodal-recurrent prostate cancer.</p><p><strong>Patients and methods: </strong>This study included 173 patients that underwent sLND between 2005 and 2019. Postoperative complications were reported according to Clavien-Dindo-Classification (CDC). Health-related quality of life (QoL) was assessed prospectively using a validated questionnaire (EORTC QLQ-C30). Postoperative urinary incontinence was quantified with the assessment of pad usage and the ICIQ-SF questionnaire.</p><p><strong>Results: </strong>The any-grade complication rate after sLND was 67% (n = 115 patients). A total of patients (n = 42) had severe postoperative complications (CDC grade ≥IIIa). No grade V complications were reported. The number of lymph nodes removed was higher in patients with any-grade complications (median 32 versus 25, p = 0.03), while the number of lymph node metastases was higher in patients with severe complications (median 7 versus 3, p = 0.03). However, no clinical parameter was independently associated with complications. A total of 56% patients did not require any pads postoperatively. Median postoperative ICIQ-SF score was 5 and was higher in patients with any prior radiation (median 6 versus 0, p = 0.03). Radical prostatectomy as primary therapy (p = 0.01) and any prior radiation (p = 0.01) were independent predictors of any incontinence. Patients' QoL was rated as moderate, with an impairment in QoL in 39% of the follow-up cohort.</p><p><strong>Conclusion: </strong>SLND is a treatment option in selected patients with nodal-recurrent prostate cancer with considerable complication rates and possible functional impairments that need to be discussed with the patient when balancing the indication for this metastasis-directed treatment option.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"79-90"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145355518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three Therapeutic Modalities for Advanced Ovarian Cancer: Real-World Data from a Certified Oncological Center.","authors":"Sara Tato Varela, Walther Christian Kuhn","doi":"10.1159/000552934","DOIUrl":"10.1159/000552934","url":null,"abstract":"<p><strong>Introduction: </strong>Traditionally, advanced ovarian cancer can be approached from two different therapeutic point of views: a radical surgery aimed at removing all macroscopic tumor followed by a systemic therapy (URS) or a neoadjuvant platinum-based chemotherapy followed by debulking surgery after achieving a response (NACT/IDS). These two options may not be enough, especially when taking into account the current existence of effective and good tolerated maintenance therapies that can also be applied in patients who do not undergo surgery.</p><p><strong>Methods: </strong>We performed a retrospective analysis of advanced epithelial ovarian cancer patients (FIGO stage IIIC-IV) treated in our certified oncological center over the last 7 years.</p><p><strong>Results: </strong>Patients allocated to NACT/IDS showed significantly higher performance status measured with the Eastern Cooperative Oncology Group (ECOG) scale on average as well as significantly higher CA125 value upon diagnosis. Histological types or age did not significantly differ. No significative differences were found when comparing the length of the surgery, days at intensive care, or need for blood transfusion, but patients subjected to NACT/IDS were less prone to have \"bulky\" lymph nodes that needed extirpation or intestinal resections. A complete macroscopic tumor resection was achieved more frequently in the URS group. Patients on the URS group showed significantly higher overall survival (OS) and progression-free survival (PFS). OS and PFS in the nonsurgical group were similar to those in the NACT/IDS group.</p><p><strong>Conclusion: </strong>Radical surgery should take place whenever success, measured as no-residual tumor, is deemed as a feasible option. Several factors should be taken into place when offering a patient a URS, both patient- (age, performance status, comorbidities) and disease-related. NACT is a good alternative for patients who are not surgical candidates when taking the previously mentioned factors into account. It should be noted that IDS is also aimed at leaving no macroscopic tumor burden, and that not all responses to NACT (objectified by tumor markers or imaging) may be enough to ensure a complete cytoreduction. Moreover, the available maintenance therapies that impact OS could play a relevant role in patients who are not suited for surgery at all, achieving long remission periods with good quality of life. More studies are needed in this field.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"357-369"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148284017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing a Multimodal Model for Predicting Lymphovascular Invasion in Breast Cancer Using Deep Transfer Learning Based on Ultrasound and Dynamic Contrast-Enhanced Magnetic Resonance Imaging.","authors":"Miaomiao He, Feifei Zhu, Feng Jiang, Yinhua Liu, Yuxin Guo, Yuan Yang, Hao Jiang, Fei Xiong, Weibo Cheng, Zhengyuan Xu, Biaohu Liu","doi":"10.1159/000553438","DOIUrl":"10.1159/000553438","url":null,"abstract":"<p><strong>Introduction: </strong>Develop a multimodal model based on ultrasound (US) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data for predicting lymphovascular invasion (LVI) in breast cancer.</p><p><strong>Method: </strong>A total of 326 patients with breast cancer were enrolled in this retrospective study. All participants underwent preoperative US and DCE-MRI. Data from Center 1 (n = 167) were divided into a training set and an internal validation set, while data from Center 2 (n = 159) were used as the external validation set for analysis. A fusion feature set was constructed from intratumoral regions of US and DCE-MRI using deep transfer learning (DTL) features. Among three machine learning models - support vector machine, k-nearest neighbors, and multi-layer perceptron (MLP) - the MLP classifier trained with a feature subset selected via LASSO achieved optimal performance across multiple feature selection methods and was thus designated as the final model. The diagnostic performance and clinical utility of the multimodal model were validated and assessed through the area under the receiver operating characteristic curve and decision curve analysis. Model interpretability was assessed using Shapley Additive Explanations (SHAP).</p><p><strong>Result: </strong>Results indicate that the multimodal model, utilizing DTL features from US and DCE-MRI within the tumor region, demonstrates outstanding performance in classifying LVI in breast cancer. The area under the curve (AUC) values of the model were 0.987 in the training set, 0.967 in the internal validation set, and 0.942 in the external validation set. Its performance was significantly better than the models using DTL features derived from single-region US (AUC: 0.966, 0.852, 0.789) or DCE-MRI (AUC: 0.936, 0.716, 0.746), indicating great value for clinical application.</p><p><strong>Conclusion: </strong>Multimodal models based on DTL features can accurately distinguish LVI status in breast cancer patients. This model demonstrates promising application prospects in distinguishing LVI in breast cancer, with its value lying in effectively enhancing diagnostic accuracy and robustness.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"377-394"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148423050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}